Less than one in 10 patients eligible to benefit from weight-loss injections such as Wegovy are able to get them, states the global health agency as it issues its first advice on the therapies.
Considering in excess of 1,000,000,000 people worldwide currently living with obesity, it is calling for increased and just access to GLP-1 medication.
According to forecasts, in excess of 2,000,000,000 are projected to be living with obesity by 2030 unless action is taken.
"The new guidelines affirms that excess weight is a long-term condition that can be addressed with comprehensive and ongoing support," stated the agency's head Tedros Adhanom Ghebreyesus.
High costs, constrained manufacturing, and supply-chain constraints are major barriers to broad access to the injections that can assist patients in reducing significant weight, notes the agency.
Skinny Jab Shortage
Despite the present best projected scenario, the supply of such drugs might only reach around 100 million people – under 10% of those who need them, per the WHO.
The advice encourages nations and manufacturers to expand availability, through approaches including patent sharing.
Exclusive production rights on the active ingredient – the primary component of a leading brand – is scheduled to end in a number of countries in 2026.
The Way Weight-Loss Injections Work
The injections imitate a natural hormone to delay gastric emptying, suppress the appetite and increase satiety so individuals reduce food intake.
Individuals typically start to lose weight in the initial weeks of beginning the regular doses.
Evidence indicates users may put most of the weight back on a year later of halting the treatment, because their typical appetite resume.
To be above a healthy weight increases your chance for experiencing diseases, like type 2 diabetes, heart disease, stroke, and specific malignancies.
Excess weight impacts people in all nations and was responsible for over three and a half million fatalities worldwide in 2024, according to the WHO.
